• Editors
  • Scope
  • Current Issue
  • Archive
  • Instruction for Author
  • Principles and Policies of transparency
  • Policies of corrections and retractions
  • EndNote style

2013 (v.21 no.2)

The Journal of Korean Society for Clinical Pharmacology and Therapeutics

Korean Society for Clinical Pharmacology and Therapeutics
ISSN: 1225-5467

  • Pharmacokinetics and Safety of Levodropropizine Controlled Release Tablet after Repeated Dosing in Healthy Male Volunteers

    Sangil Jeon, Jongtae Lee, Taegon Hong, Jeongki Paek, Seunghoon Han, Dong-Seok Yim

    J Korean Soc Clin Pharmacol Ther | v.21, no.2, pp.113-119, Dec, 2013


    Background: Levodropropizine is non-opioid agent whose peripheral antitussive action may result from
    its modulation of sensory neuropeptide levels. Currently, levodropropizine 60 mg is taken three-times daily.
    A controlled release formulation of levodropropizine (levodropropizine CR) 90 mg was developed, which
    can be taken twice daily. The aim of this study was to evaluate the safety and pharmacokinetic
    characteristics after multiple oral administrations of levodropropizine CR 90 mg tablets in healthy male
    Methods: A randomized, open-label, cross-over study was conducted in 24 healthy male volunteers. Each
    subject received levodropropizine syrup 60 mg three times daily or levodropropizine CR 90 mg twice daily
    for 3 days. Blood samples for pharmacokinetic analysis were collected pre-dose and up to 24 hours on
    day 4. Pharmacokinetic analysis was conducted by non-compartmental method. Safety assessments
    including monitoring adverse events, laboratory tests, vital signs, physical examinations and ECGs were
    performed throughout the study.
    Results: A total of 20 male volunteers completed the study. The maximum steady-state plasma
    concentration (Css,max) of levodropropizine syrup and levodropropizine CR were 313.28 ng/mL and 285.31
    ng/mL and time to reach Css,max (Tmax,ss) were 0.48 hr and 0.88 hr, respectively. The area under the
    concentration-time curve to the last measured concentration of two groups were 2345.36 hr × ng/mL and
    2553.81 hr × ng/mL, respectively. There was no serious adverse event.
    Conclusion: Levodropropizine CR 90 mg tablet was safe and well-tolerated when administered twice daily
    for 3 days. No statistically significant differences were seen in Css,max and AUCss,24hr between the two
    formulations. This study provided pharmacokinetic evidences that the twice-daily dosing regimen of
    levodropropizine 90 mg may substitute the conventional 3-times-daily regimen of levodropropizine 60 mg.


    Levodropropizine, Pharmacokinetics, Non-compartmental analysis